Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



Lepu Biopharma Co., Ltd. 樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

NOTICE OF 2021 ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the 2021 annual general meeting (the "**AGM**") of Lepu Biopharma Co., Ltd. (the "**Company**") will be held at Conference Room, Building 7, No. 37 Chaoqian Road, Changping District, Beijing, PRC on Tuesday, June 21, 2022 at 10:00 a.m. for the following purposes:

ORDINARY RESOLUTIONS

- 1. To consider and approve the resolution on the report of the Board of Directors of the Company for the year 2021.
- 2. To consider and approve the resolution on the report of the Board of Supervisors of the Company for the year 2021.
- 3. To consider and approve the resolution on the annual report of the Group for the year 2021.
- 4. To consider and approve the resolution on the financial accounts report of the Group for the year 2021.
- 5. To consider and approve the resolution on the financial budget of the Group for the year 2022.
- 6. To consider and approve the resolution on the annual profit distribution plan of the Company for the year 2021.
- 7. To consider and approve the re-appointment of PricewaterhouseCoopers as the auditor of the Company for 2022, for a term commencing from the date of approval at the AGM until the conclusion of the 2022 annual general meeting of the Company, and authorize the Board to determine the specific matters, including but not limited to their remunerations, in relation to such re-appointment.

SPECIAL RESOLUTION

8. To consider and approve the resolution on the grant of a general mandate to the Board to issue shares.

Details of the above resolutions are set out in the circular of the Company to be published on May 30, 2022 in relation to the AGM. Unless otherwise indicated, capitalized terms used in this notice shall have the same meanings as those defined in the circular.

By order of the Board

Lepu Biopharma Co., Ltd.

Dr. Pu Zhongjie

Chairman of the Board and Executive Director

Shanghai, the PRC May 30, 2022

Notes:

- All resolutions at the AGM will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The results of the poll will be published on the websites of the Company at www.lepubiopharma.com and Hong Kong Exchanges and Clearing Limited at www.hkexnews.hk after the AGM.
- 2. Any shareholder entitled to attend and vote at the AGM convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not be a shareholder of the Company.
- 3. In view of the ongoing COVID-19 pandemic, the Company strongly recommends Shareholders of the Company to exercise your voting rights by appointing the chairman of the AGM as your proxy to vote on the relevant resolution(s) at the AGM as an alternative to attending the AGM in person.
- 4. In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and returned to the Company's head office and principal place of business in the PRC, at 2nd Floor, Building 41, Lane 518, Xinzhuan Road, Songjiang District, Shanghai, PRC (for holders of Domestic Shares) or the H Share registrar of the Company in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (for holders of H shares), at least 24 hours before the AGM (i.e. before 10:00 a.m. on Monday, June 20, 2022) or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude a shareholder from attending and voting at the AGM or any adjourned meeting thereof should he/she so wish.
- 5. For the purpose of determining the list of shareholders who are entitled to attend the AGM, the register of members of the Company will be closed from Saturday, May 21, 2022 to Tuesday, June 21, 2022, both days inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the AGM, unregistered holders of the shares shall ensure all properly completed transfer documents accompanied by the relevant share certificates must be lodged with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Friday, May 20, 2022 for registration.
- 6. In case of joint shareholders, the vote of the senior joint shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint shareholder(s) and for this purpose, seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding.

- 7. Shareholders who attend the meeting in person or by proxy shall bear their own travelling and accommodation expenses.
- 8. A shareholder or his/her proxy should produce proof of identity when attending the AGM.
- 9. References to date and time in this notice are to Hong Kong dates and time.

As at the date of this notice, the Board comprises Dr. Pu Zhongjie (Chairman), Dr. Sui Ziye (Chief Executive Officer) and Dr. Hu Chaohong (Co-Chief Executive Officer) as executive Directors; Ms. Pu Jue, Mr. Yang Hongbing and Mr. Lin Xianghong as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.